Skip to main content

Andrew Berchuck, MD

Andrew Berchuck, MD
James M. Ingram Professor of Gynecologic Oncology
Campus Mail: 25171 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765
Email: berch001@mc.duke.edu

Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the James M. Ingram Distinguished Professorship. He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers. This includes minimally invasive laparoscopic surgical approaches. He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. He has published over 300 peer-reviewed papers in these areas. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) use of genomic approaches  to elucidate the molecular heterogenetity of ovarian cancer. Thirty fellows and residents have worked in his lab, several of whom are now funded investigators. His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncology and the International Gynecologic Cancer Society. Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006. He has served as editor of several books in the field including Principles and Practice of Gynecologic Oncology. Dr. Berchuck also has a major commitment to national activities, and was President of the Society of Gynecologic Oncology in 2008. He served as chair of the scientific advisory committee of the Ovarian Cancer Research Fund (http://www.ocrf.org) in New York City. Finally, he is also head of the steering committee of the international Ovarian Cancer Association Consortium (OCAC), a group of 50 case-control studies that are working together to identify ovarian cancer susceptibility polymorphisms (www.srl.cam.ac.uk/consortia/ocac/index.html).

Education and Training

  • M.D., Case Western Reserve University, 1980

Research

Dr Berchuck is interested in the molecular pathogenesis of ovarian and endometrial cancer. 

View Publications

Publications

Notaridou, M, Quaye, L, Dafou, D, Jones, C, Song, H, Høgdall, E, Kjaer, SK, Christensen, L, Høgdall, C, Blaakaer, J, McGuire, V, Wu, AH, Van Den Berg, DJ, Pike, MC, Gentry-Maharaj, A, Wozniak, E, Sher, T, Jacobs, IJ, Tyrer, J, Schildkraut, JM, Moorman, PG, Iversen, ES, Jakubowska, A, Mędrek, K, Lubiński, J, Ness, RB, Moysich, KB, Lurie, G, Wilkens, LR, Carney, ME, Wang-Gohrke, S, Doherty, JA, Rossing, MA, Beckmann, MW, Thiel, FC, Ekici, AB, Chen, X, and Beesley, J et al. "Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer." Int J Cancer 128, no. 9 (May 1, 2011): 2063-2074.

Full Text

Amankwah, EK, Kelemen, LE, Wang, Q, Song, H, Chenevix-Trench, G, Australian Ovarian Cancer Study Group, , Beesley, J, Webb, PM, Australian Cancer Study (Ovarian Cancer), , Pearce, CL, Wu, AH, Pike, MC, Stram, DO, Chang-Claude, J, Wang-Gohrke, S, Ness, RB, Goode, EL, Cunningham, JM, Fridley, BL, Vierkant, RA, Tworoger, SS, Whittemore, AS, McGuire, V, Sieh, W, Gayther, SA, Gentry-Maharaj, A, Menon, U, Ramus, SJ, Rossing, MA, Doherty, JA, Goodman, MT, Carney, ME, Lurie, G, Wilkens, LR, and Kjær, SK et al. "Prostate cancer susceptibility polymorphism rs2660753 is not associated with invasive ovarian cancer." Cancer Epidemiol Biomarkers Prev 20, no. 5 (May 2011): 1028-1031.

Full Text

Goode, EL, White, KL, Vierkant, RA, Phelan, CM, Cunningham, JM, Schildkraut, JM, Berchuck, A, Larson, MC, Fridley, BL, Olson, JE, Webb, PM, Chen, X, Beesley, J, Chenevix-Trench, G, Sellers, TA, Ovarian Cancer Association Consortium, , and Australian Ovarian Cancer Study Group, . "Xenobiotic-Metabolizing gene polymorphisms and ovarian cancer risk." Mol Carcinog 50, no. 5 (May 2011): 397-402.

Full Text

Huang, Z, Yamaguchi, K, Berchuck, A, and Murphy, SK. "Abstract 3014: Quantitative accuracy of Illumina HumanMethylation27 Infinium BeadChip data assessed by pyrosequencing." Cancer Research 71, no. 8 Supplement (April 15, 2011): 3014-3014.

Full Text

Teoh, D, Ayeni, TA, Rubatt, JM, Adams, DJ, Grace, L, Starr, MD, Barry, WT, Berchuck, A, Murphy, SK, and Secord, AA. "Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells." Gynecol Oncol 121, no. 1 (April 2011): 187-192.

Full Text

Berchuck, A, and Einstein, MH. "Prevention and early detection of cancer." Gynecol Oncol 121, no. 1 (April 2011): 1-.

Full Text

Carver, DK, Barnes, HJ, Anderson, KE, Petitte, JN, Whitaker, R, Berchuck, A, and Rodriguez, GC. "Reduction of ovarian and oviductal cancers in calorie-restricted laying chickens." Cancer Prev Res (Phila) 4, no. 4 (April 2011): 562-567.

Full Text

Lancaster, J, Chen, D, Marchion, D, Xiong, Y, Berchuck, A, Judson, P, Bosquet, JG, Wenham, R, Apte, S, and Fulp, W. "BAD apoptosis pathway expression and survival from cancer." GYNECOLOGIC ONCOLOGY 121, no. 1 (March 2011): S24-S24.

Full Text

Berchuck, A, Pike, M, Schildkraut, J, and Pearce, C. "Common single-nucleotide polymorphisms in the BNC2, HOXD1 and MERIT40 regions contribute significantly to racial differences in ovarian cancer incidence." GYNECOLOGIC ONCOLOGY 121, no. 1 (March 2011): S7-S7.

Full Text

Sfakianos, G, Yan, J, Whitaker, R, Murphy, S, and Berchuck, A. "Concordant gene expression profiles in matched primary and recurrent serous ovarian cancers predict platinum response." GYNECOLOGIC ONCOLOGY 121, no. 1 (March 2011): S46-S46.

Full Text

Pages